ImmunovantIMVT
About: Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Employees: 207
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
305% more call options, than puts
Call options by funds: $73.9M | Put options by funds: $18.2M
34% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 29
12% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 60
3% more funds holding
Funds holding: 180 [Q3] → 185 (+5) [Q4]
2.35% more ownership
Funds ownership: 53.72% [Q3] → 56.06% (+2.35%) [Q4]
9% less capital invested
Capital invested by funds: $2.24B [Q3] → $2.04B (-$204M) [Q4]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 6 (-1) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
UBS Colin Bristow 17% 1-year accuracy 2 / 12 met price target | 18%upside $17 | Neutral Downgraded | 22 Apr 2025 |
B of A Securities Jason Gerberry 26% 1-year accuracy 5 / 19 met price target | 128%upside $33 | Buy Maintained | 20 Mar 2025 |
HC Wainwright & Co. Douglas Tsao 17% 1-year accuracy 30 / 172 met price target | 253%upside $51 | Buy Reiterated | 19 Mar 2025 |
Financial journalist opinion









